UPDATE: Oppenheimer Starts Gain Therapeutics (GANX) at Outperform

Oppenheimer analyst Hartaj Singh initiates coverage on Gain Therapeutics (NASDAQ: GANX) with a Outperform rating and a price target of $30.00.

The analyst comments "We are initiating on Gain Therapeutics (GANX) with an Outperform and $30 PT. Our thesis centers on GANX's proprietary platform (Mdmix/See-Tx) that could unveil historically difficult targets and highly potent small molecule medicines, vs. a traditional process that has been fairly inefficient. Of GANX's pipeline, we believe Morquio B/GM1-gangliosidosis could be diseases where GANX could first establish clinical proof-of-concept while its Parkinson’s program has the biggest potential commercial opportunity. We also view GANX's approach as potentially favoring the historical probability of success of drug development, especially given the platform's flexibility in identifying uncorrelated targets/structurally distinctive molecules. We also cite GANX's experienced/execution-focused management and are bullish on the approach."

For an analyst ratings summary and ratings history on Gain Therapeutics click here. For more ratings news on Gain Therapeutics click here.

Shares of Gain Therapeutics closed at $13.98 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Gain Therapeutics, Inc. (GANX) Tops Q2 EPS by 3c